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Abstract 44 
 45 
Background 46 
 47 
Thyroid Eye Disease (TED) develops in around 25% of those with Graves’ Disease 48 
(GD). Patients with TED may present late to ophthalmologists, when debilitating 49 
orbital inflammatory changes have already occurred. The reasons for this are 50 
multifactorial, but poor knowledge of TED in GD patients may be contributory. We 51 
aimed to assess the knowledge of TED in those with established TED, GD without 52 
orbitopathy and control subjects. 53 
 54 
Methods 55 
 56 
A validated, anonymised questionnaire, with 20 knowledge-based questions, was 57 
prospectively completed by 100 GD patients, 100 TED patients and 100 age- and 58 
sex-matched controls (with no history of thyroid disease or TED) in two tertiary 59 
referral Thyroid and Orbital Diseases clinics. Demographic data and details of 60 
highest educational level, disease duration and follow-up were gained. Residence 61 
post-code was used to determine Index of Multiple Deprivation (2015) quintile. 62 
Knowledge score was established for each of the study groups of interest. Statistical 63 
analysis was undertaken with Kruskal-Wallis test, χ-squared test and multivariable 64 
logistic regression.  65 
 66 
Results 67 
 68 
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There was no significant difference in median knowledge scores (out of 20) between 69 
GD (13.71, range 9-18) and TED (14.25, range 9-18) patients. However, both groups 70 
had significantly higher scores than controls (11.53, range 4-16) (p<0.001). 71 
Multivariable analysis determined no particular independent factor associated with 72 
lower knowledge score. There were a number of important areas in which patient 73 
knowledge of TED was poor. While almost all (99% TED, 89% GD) knew that TED 74 
involved orbital tissue inflammation, a large proportion (60% TED, 50% GD) were 75 
unaware that TED may develop in the absence of hyperthyroidism or did not know 76 
that cigarette smoking is associated with more severe TED (21%TED, 33% GD).  77 
 78 
Conclusions 79 
 80 
TED patients had equivalent levels of TED knowledge to GD patients without 81 
orbitopathy. While subjects in both disease groups had greater knowledge than 82 
controls, each had significant misconceptions regarding aspects of TED diagnosis, 83 
management and treatment. These findings should guide the future provision of 84 
patient information for TED, with educational materials being targeted to address 85 
existing gaps in knowledge. 86 
 87 
 88 
 89 
 90 
 91 
 92 
 93 
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Introduction 94 
 95 
Previous studies have demonstrated that increased patient knowledge of a disease 96 
results in earlier presentation to health services, better insight into that condition, 97 
reduced anxiety and increased compliance with treatment (1). This is especially 98 
important in Thyroid Eye Disease (TED), an inflammatory condition of the orbital 99 
tissues which occurs in around 25% of those with the autoimmune hyperthyroidism, 100 
Graves’ Disease (GD) (2). GD develops before or at the same time as TED in 101 
around 80% of cases (3) and of those with GD who do develop TED, around 70% 102 
will develop orbital manifestations within 12 months of their GD diagnosis (4).  103 
 104 
However, evidence also exists that patients present late with TED, with a mean time 105 
from development of ocular symptoms to TED diagnosis of 9 months (5). This 106 
represents a lost opportunity for early intervention (e.g. with early 107 
immunosuppression or targeted smoking cessation) with the possible prevention or 108 
reduction of the subsequent physically and psychosocially debilitating effects of TED. 109 
 110 
While it might be expected that a proportion of patients with GD will search the 111 
internet for information about ocular problems related to autoimmune thyroid 112 
disease, it has been demonstrated that online information regarding TED is of poor 113 
readability. This means that patients may not be able to fully understand the potential 114 
morbidity associated with TED, nor the  available strategies to reduce the impact of 115 
early symptoms, such as the use of topical lubricants, as well as those to prevent 116 
development of severe TED, including smoking cessation (6).   117 
 118 
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To our knowledge, no study to date has objectively assessed the level of knowledge 119 
of TED either in patients with TED or those with GD, who are at risk of subsequently 120 
developing TED. We aimed to assess and compare TED knowledge between GD 121 
patients (with and without ocular or orbital manifestations) and controls, to identify 122 
any misconceptions about TED and to determine factors that may predict poorer 123 
understanding of TED.  124 
 125 
Methods 126 
 127 
The study model was based on previous research assessing patient knowledge of 128 
glaucoma by Danesh-Meyer et al (2008) (1). Recruitment sites for the study were the 129 
Thyroid Clinic of University Hospital Birmingham, UK (TED and GD subjects) and the 130 
Orbital Diseases Clinic of Birmingham and Midland Eye Centre, UK (TED subjects 131 
only). The study followed the principles of the Declaration of Helsinki and was 132 
approved by the research and development departments of both hospital trust 133 
recruitment sites.  134 
 135 
Study subjects were recruited into three groups – those with established TED, those 136 
with GD but no manifestations of ocular or orbital disease, and age- and sex-137 
matched controls. Patients were eligible for inclusion in the GD group if they had this 138 
diagnosis made by a consultant endocrinologist on the basis of abnormal thyroid 139 
function tests (overt hyper- or hypothyroidism) either at the time of recruitment, or 140 
previously, as well as raised concentrations of thyroid stimulating hormone receptor 141 
(TSH-R) antibodies. Overt hyperthyroidism was defined as undetectable serum TSH 142 
concentrations with raised serum free T4 and or free T3 concentrations. Overt 143 
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hypothyroidism was defined as raised serum TSH concentrations with reduced 144 
serum fT4 concentrations. Subjects were eligible to be included in the TED group if 145 
they had the above criteria for GD, in addition to a diagnosis of TED made by a 146 
consultant ophthalmologist, for 6 months or more on the basis of signs of orbitopathy 147 
(e.g. proptosis, periocular swelling, strabismus/ocular movement restriction). The 148 
control group was recruited randomly from patients, family members and friends 149 
attending non-thyroid and non-orbit out-patient clinics at University Hospital 150 
Birmingham. Exclusion criteria for control subjects included a personal or family 151 
history of thyroid dysfunction or TED. 152 
 153 
An anonymized questionnaire was developed for GD, TED and control subjects 154 
(Supplementary Data), the first section of which sought demographic information 155 
(age, sex, ethnic origin), level of educational attainment (no qualifications, secondary 156 
school education, vocational qualifications, university degree or higher degree) and 157 
first language spoken at home. Residence post code was used to determine an 158 
Index of Multiple Deprivation (IMD) 2015 score using the GeoConvert website 159 
(www.geoconvert.ukdataservice.ac.uk). The questionnaire also asked if information 160 
about TED had been sought and, if relevant, the sources of information used to 161 
research TED. Finally, subjects were questioned about their GD and TED diagnosis 162 
and duration, the treatment they had received (anti-thyroid drugs, radioiodine, 163 
thyroidectomy) and, in the case of TED subjects, whether they had received 164 
immunosuppressive therapy, orbital radiotherapy or surgery (orbital decompression, 165 
squint or eyelid surgery).  166 
 167 
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The second section of the questionnaire comprised 20 true/false format questions. 168 
These questions were written and discussed at a focus group of two endocrinologists 169 
and two ophthalmologists, with the aim being to explore patient knowledge of TED 170 
diagnosis, disease-modifying factors and treatment. Feedback on the questions was 171 
requested from members of the UK-based TED charity, Thyroid Eye Disease 172 
Charitable Trust (TEDct) to ensure that the questions were of sufficient quality and 173 
importance. The questionnaire was piloted on 10 TED patients prior to the 174 
commencement of the full study. Following this validation period the questionnaire 175 
was personally administered to, and completed by, all study subjects while they were 176 
in the out-patient clinic environment, ensuring that it was not possible for participants 177 
to search for the correct answers to questions while completing the questionnaire.     178 
 179 
Statistical analysis was undertaken for non-normally distributed data using Mann-180 
Whitney test (2 groups) and Kruskall-Wallis test (≥3 groups) for continuous data and 181 
χ-squared test for categorical data. Multivariable logistic regression was undertaken 182 
to determine if differences in knowledge scores were associated with any 183 
independent variable. Analyses were undertaken using Prism version 5.0 (GraphPad 184 
Software, La Jolla, CA, USA) and SPSS version 18 (IBM, Chicago, IL). P <0.05 was 185 
considered statistically significant. 186 
 187 
Results 188 
 189 
The study was undertaken over a 12-month period with 300 consecutive subjects 190 
recruited. There were 100 TED, 100 GD and 100 control subjects in each study 191 
group. The groups were well-matched for age and gender.  192 
9 
 
 193 
The overall TED knowledge scores for each of the study groups are shown in Figure 194 
1. Median knowledge score (out of 20) in the TED group was 14.25 (range 9-18), in 195 
the GD group 13.71 (range 9-18) and in the control group 11.53 (range 4-16). There 196 
was no significant difference between the scores of the TED and GD group, but both 197 
of these groups scored significantly higher than the controls (P<0.001). The 198 
proportion of correct answers for each of the groups was significantly different for 199 
some, but not all, of the 20 questions (Table 1). 200 
 201 
Univariate analyses determined no significant difference in TED knowledge scores 202 
according to age, gender, ethnicity, level of highest educational attainment, first 203 
language or IMD 2015 score. Similarly, there was no significant difference in TED 204 
knowledge scores in relation to disease duration following diagnosis of GD or TED, 205 
the duration of follow-up in the Thyroid or Orbit Clinic, whether they had ever been 206 
seen and assessed by an ophthalmologist, whether they had received steroids or 207 
orbital radiotherapy for TED or indeed whether they had undergone emergency or 208 
rehabilitative surgery for TED. Furthermore, multivariable analysis determined that 209 
there was no factor independently associated with higher or lower TED knowledge 210 
score in any of the study groups.  211 
 212 
Discussion 213 
 214 
To our knowledge, this is the first study to evaluate the level of TED knowledge in 215 
GD patients with and without orbitopathy. While GD and TED patients scored 216 
significantly higher than controls from a statistical point of view, the actual practical 217 
10 
 
difference in knowledge scores (2 to 3 points higher than the controls) for GD and 218 
TED patients is likely to be insignificant. Indeed, TED patients only scored 219 
significantly higher than controls in 13 out of the 20 questions (65%), while GD 220 
patients scored higher than controls in 8 out of the 20 questions (40%).  221 
 222 
It is perhaps surprising that those with a longer duration of GD or TED, or TED that 223 
had required steroid treatment, orbital radiotherapy or surgical intervention, did not 224 
score more highly. Similarly, those with a shorter duration of GD or TED may have 225 
been anticipated to score more highly, as they may have been expected to have 226 
sought out relevant information more recently, or more recently had contact with their 227 
endocrinologist or ophthalmologist. However, this did not prove to be the case. This 228 
may also indicate that recent attempts by endocrinologists and ophthalmologists to 229 
educate those with GD and TED were unsuccessful.  230 
 231 
In univariate analysis no significant difference was observed in knowledge scores by 232 
age, sex, ethnicity, highest educational attainment, first language, IMD 2015 score or 233 
duration of follow-up in the Thyroid or Orbit Clinic. Likewise, no factor was found to 234 
be independently associated with higher or lower TED knowledge scores on 235 
multivariable analyses. 236 
 237 
Studies evaluating patient knowledge of other diseases have noted that higher 238 
educational level and socioeconomic status are associated with earlier presentation 239 
to medical services, increased knowledge of disease and better compliance with 240 
treatment regimens (1). Other studies have shown higher knowledge scores for 241 
diseases such as glaucoma and diabetic retinopathy in those whose first language is 242 
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English (1, 7, 8), mainly as the questionnaires in these studies were written in 243 
English. We did not find such an association in our study. Studies assessing 244 
conditions such as uveitis have also determined patient knowledge of their own 245 
condition to be poor (9). 246 
 247 
Significant misconceptions were identified in key areas that may impact upon drivers 248 
for worse TED in GD patients, such as the importance of good thyroid function 249 
control and the crucial role of smoking in TED. While both GD and TED patients 250 
scored significantly higher than controls in terms of demographic aspects of TED 251 
(e.g. questions 4 and 7), only 50% of GD and 40% of TED patients knew that TED 252 
does not necessarily only occur in those with hyperthyroidism (question 1). This 253 
might result in euthyroid or hypothyroid GD patients becoming complacent in having 254 
a perception that they are less likely to develop TED, even if experiencing ocular 255 
symptoms. Likewise, whilst GD and TED subjects scored relatively highly regarding 256 
TED pathogenesis (e.g. questions 8, 12, 16, 17 and 20), only 67% of GD and 79% of 257 
TED patients knew about the association between smoking and more severe TED. 258 
Furthermore, knowledge of the surgical management of TED appeared poor, with 259 
GD and TED subjects overestimating the effectiveness of thyroidectomy in treating 260 
TED (question 9), overestimating the tendency of radioiodine to worsen TED 261 
(question 15), and demonstrating poor knowledge regarding the role of orbital 262 
radiotherapy and orbital decompression (questions 18 and 19) in the management of 263 
some TED patients. It is also important to note that around two-thirds of GD and TED 264 
subjects perceived that psychological stress made TED worse (question 5). While no 265 
published literature currently exists regarding an association between stress and 266 
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TED, the weighting that the GD and TED patient groups gave to this area suggests 267 
that it may be an interesting avenue for further research. 268 
 269 
Those with TED are known to have delay to presentation from their initial experience 270 
of ocular symptoms, with recent Europe-wide data determining that the median 271 
period is 9 months (although with a range of 0 to 552 months) (5). Similarly, in a 272 
multicentre United Kingdom audit, the mean time from initial symptoms of TED to 273 
diagnosis was over 27 months, and from first visit to any doctor with ocular 274 
symptoms to TED diagnosis of over 9 months (10). The reasons for this are 275 
multifactorial, but may include the patient themselves not presenting sufficiently early 276 
as initial symptoms of grittiness and soreness may be perceived as being due to 277 
‘allergy’ or ‘conjunctivitis’. Nevertheless, this duration is shorter than in earlier studies 278 
from 15 years ago when the median time from symptoms to diagnosis was 16 279 
months (with a range of 0 to 720 months) (11). This is important, as studies have 280 
shown that treatments may be more efficacious when a diagnosis of TED is made 281 
earlier (12). In addition, delay to diagnosis may result in increased time to 282 
intervention, with the possibility of developing morbidity including loss of vision, 283 
diplopia and disfigurement, but also loss of work, income (13), reduced quality of life, 284 
social status, as well as negative psychosocial consequences (14). 285 
 286 
The objectives of the Amsterdam declaration on Thyroid Eye Disease in general 287 
were to minimize the morbidity associated with TED and improve the patients’ 288 
experience and quality of life and to prevent the development of TED in people at 289 
high risk (15). There has been an increasing recognition of the importance of early 290 
diagnosis of TED, with agencies such as the UK Thyroid Eye Disease Amsterdam 291 
13 
 
Declaration Implementation Group (TEAMeD) advocating that GD patients be issued 292 
with ‘early warning cards’ to prompt them to seek urgent assessment if ocular 293 
symptoms develop (16). Clinical assessment tools, such as Diagnosis of Graves' 294 
Orbitopathy (DiaGO) (17) to aid endocrinologists in making an earlier diagnosis of 295 
TED in GD patients have also been devised. However, if patients do not adequately 296 
understand their medical condition, these may be of lesser utility. Patient and public 297 
involvement in TED has been attempted (18) and in the United Kingdom there are 298 
support agencies such as Thyroid Eye Disease Charitable Trust (TEDct) and British 299 
Thyroid Foundation (BTF). There are also numerous websites with patient 300 
information for people with TED. However, studies have indicated that the actual 301 
readability of the information on these websites is poor, and therefore may not be 302 
understood by GD and TED patients (6). 303 
 304 
Endocrinologists and ophthalmologists need to have an understanding of the level of 305 
knowledge their patients with GD, with and without ocular manifestations, have about 306 
TED. In the former group of patients good understanding may result in medical 307 
advice being sought in good time. In the latter, patient knowledge and understanding 308 
may result in better motivation to make necessary lifestyle modifications, adhere to 309 
treatment regimens and have an awareness of the available treatment modalities. 310 
Endocrinologists and ophthalmologists also need to know which areas of TED 311 
knowledge may be deficient, so that these can be effectively targeted and 312 
emphasized during the usually short clinic attendances that may be afforded in busy 313 
out-patient clinics.  Despite time and resource limitations we as physicians still have 314 
responsibility for ensuring that we appropriately counsel our patients regarding 315 
important aspects of GD with and without orbitopathy.  316 
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 317 
The answers given by GD and TED patients in this study demonstrate a number of 318 
misconceptions that endocrinologists and ophthalmologists need to be aware of and 319 
try to overcome. Our findings indicate the need to tailor educational efforts and 320 
materials to deficient areas and to focus on important aspects of TED knowledge 321 
with the aim of dispelling misconceptions. 322 
 323 
We recommend that endocrinologists and ophthalmologists undertake similar 324 
surveys of the knowledge of their own GD and TED patients to more accurately 325 
gauge patient knowledge, as a surrogate of local performance in GD and TED 326 
patient education and information retention. We acknowledge that it is not possible 327 
for us to guarantee the wider applicability of the results of this survey to other 328 
national and international specialist clinics. However, the city in which the study was 329 
undertaken is a very culturally and ethnically diverse region of the United Kingdom 330 
and our respondent population was large and truly represented an unbiased regional 331 
cross-section. There are also more holistic means of assessing patient knowledge 332 
beyond True/False format questionnaires (e.g. structured interviews), but our data 333 
does demonstrate ‘real-world’ responses of GD and TED patients to extremely 334 
pertinent questions regarding their presentation, assessment and treatment. 335 
 336 
In summary, this is the first study to evaluate the level of TED knowledge in GD 337 
patients with and without orbitopathy, and to provide a comparison with the 338 
knowledge levels of the public in general. GD and TED knowledge scores were 339 
significantly higher than controls from a statistical point of view, but not necessarily 340 
from a practical point of view. Significant misconceptions and knowledge ‘gaps’ in 341 
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important areas were observed. These data should be used to inform future 342 
decisions about the provision of patient information for those with GD and TED and 343 
will facilitate the tailoring of educational materials to these patients. 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
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